Pegylated interferon and ribavirin as an available variant of antiviral therapy for chronic hepatitis C in HIV Infected

Standard

Pegylated interferon and ribavirin as an available variant of antiviral therapy for chronic hepatitis C in HIV Infected. / Azovtseva, O. V.; Arhipov, G. S.; Trofimova, T. S.

в: HIV Infection and Immunosuppressive Disorders, Том 9, № 3, 2017, стр. 39-46.

Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование

BibTeX

@article{51f81d2ac08c468faaa7e3b877b63bc3,

title = "Pegylated interferon and ribavirin as an available variant of antiviral therapy for chronic hepatitis C in HIV Infected",

abstract = "Study objective was to assess the effectiveness of antiviral therapy for chronic hepatitis C in HIV patients. For this, a group of 60 HIV patients who were treated with PEGylated interferon and ribavirin for chronic hepatitis C was evaluated retrospectively. The patients were examined using general clinical, biochemical, serological, molecular-biological, and genotyping approaches. Treatment results were assessed monthly based on clinical data, viral load, and ALT activity. Sustained virologic response criteria were applied after the completion of the treatment to determine its effect. The results suggest that the use of PEGylated interferon and ribavirin is currently an affordable approach to HIV patient curing of chronic hepatitis C. The independent factors that influence the achievement of sustained virologic response include younger age, increased ALT, and lower replication activities of HCV and HIV.",

keywords = "Antiviral therapy, Hepatitis C, HIV infection",

author = "Azovtseva, {O. V.} and Arhipov, {G. S.} and Trofimova, {T. S.}",

note = "Publisher Copyright: {\textcopyright} 2017.",

year = "2017",

doi = "10.22328/2077-9828-2017-9-3-39-46",

language = "English",

volume = "9",

pages = "39--46",

journal = "ВИЧ-инфекция и иммуносупрессии",

issn = "2077-9828",

publisher = "БАЛТИЙСКИЙ МЕДИЦИНСКИЙ ОБРАЗОВАТЕЛЬНЫЙ ЦЕНТР",

number = "3",

}

RIS

TY - JOUR

T1 - Pegylated interferon and ribavirin as an available variant of antiviral therapy for chronic hepatitis C in HIV Infected

AU - Azovtseva, O. V.

AU - Arhipov, G. S.

AU - Trofimova, T. S.

PY - 2017

Y1 - 2017

N2 - Study objective was to assess the effectiveness of antiviral therapy for chronic hepatitis C in HIV patients. For this, a group of 60 HIV patients who were treated with PEGylated interferon and ribavirin for chronic hepatitis C was evaluated retrospectively. The patients were examined using general clinical, biochemical, serological, molecular-biological, and genotyping approaches. Treatment results were assessed monthly based on clinical data, viral load, and ALT activity. Sustained virologic response criteria were applied after the completion of the treatment to determine its effect. The results suggest that the use of PEGylated interferon and ribavirin is currently an affordable approach to HIV patient curing of chronic hepatitis C. The independent factors that influence the achievement of sustained virologic response include younger age, increased ALT, and lower replication activities of HCV and HIV.

AB - Study objective was to assess the effectiveness of antiviral therapy for chronic hepatitis C in HIV patients. For this, a group of 60 HIV patients who were treated with PEGylated interferon and ribavirin for chronic hepatitis C was evaluated retrospectively. The patients were examined using general clinical, biochemical, serological, molecular-biological, and genotyping approaches. Treatment results were assessed monthly based on clinical data, viral load, and ALT activity. Sustained virologic response criteria were applied after the completion of the treatment to determine its effect. The results suggest that the use of PEGylated interferon and ribavirin is currently an affordable approach to HIV patient curing of chronic hepatitis C. The independent factors that influence the achievement of sustained virologic response include younger age, increased ALT, and lower replication activities of HCV and HIV.

KW - Antiviral therapy

KW - Hepatitis C

KW - HIV infection

UR - http://www.scopus.com/inward/record.url?scp=85046634530&partnerID=8YFLogxK

U2 - 10.22328/2077-9828-2017-9-3-39-46

DO - 10.22328/2077-9828-2017-9-3-39-46

M3 - Article

AN - SCOPUS:85046634530

VL - 9

SP - 39

EP - 46

JO - ВИЧ-инфекция и иммуносупрессии

JF - ВИЧ-инфекция и иммуносупрессии

SN - 2077-9828

IS - 3

ER -

ID: 86423363